Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Angiotensin-converting-enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency. METHODS: We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death. Secondary end points included changes in the level of proteinuria and the rate of progression of renal disease. RESULTS: Of 102 patients in group 1, 22 (22 percent) reached the primary end point, as compared with 44 of 108 patients given benazepril in group 2 (41 percent) and 65 of 107 patients given placebo in group 2 (60 percent). As compared with placebo, benazepril was associated with a 43 percent reduction in the risk of the primary end point in group 2 (P=0.005). This benefit did not appear to be attributable to blood-pressure control. Benazepril therapy was associated with a 52 percent reduction in the level of proteinuria and a reduction of 23 percent in the rate of decline in renal function. The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar. CONCLUSIONS: Benazepril conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency. (ClinicalTrials.gov number, NCT00270426.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our trial confirms that the kidneyprotective effects of SGLT2 inhibitors extend to the broader population of persons with chronic kidney disease without type 2 diabetes, for whom ACE inhibitors are the only pharmacologic treatments that have been shown to prevent kidney failure.3,4”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [4]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Coresh, J., Astor, B. C., McQuillan, G., Kusek, J., Greene, T., Van Lente, F., & Levey, A. S. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32765 · Cited by 717
A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILURE
Mitch, W. E., Walser, M., Buffington, G. A., & Lemann, J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91974-7 · Cited by 459
Ruggenenti, P., Nefrologia”(GISEN), O. B. O. T. “. I. D. S. E. I., Perna, A., Mosconi, L., Pisoni, R., & Remuzzi, G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00874.x · Cited by 434
Research works printed but not linked: 4
- 2001, Chin J Nephrol, 17, 77
- Hou FF, 2005, Zhonghua Yi Xue Za Zhi, 85, 458
- Zhang GH, 2005, Zhonghua Nei Ke Za Zhi, 44, 592
- Levey AS, 2000, J Am Soc Nephrol, 11, 155A
Cited by
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationMancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Self-citationStrict Blood-Pressure Control and Progression of Renal Failure in Children
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902066 · Cited by 956
Renal tubule injury: a driving force toward chronic kidney disease
Liu, B.-C., Tang, T.-T., Lv, L.-L., & Lan, H.-Y. (2018) · Kidney International · doi:10.1016/j.kint.2017.09.033 · Cited by 913
“Blockade of the RAS has become the mainstay therapy for the preservation of CKD.(90) Ang II is the major bioactive product of the RAS.”
BackgroundInfluentialKidney fibrosis: from mechanisms to therapeutic medicines
Huang, R., Fu, P., & Ma, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01379-7 · Cited by 781
Renin-angiotensin system and cardiovascular risk
Schmieder, R. E., Hilgers, K. F., Schlaich, M. P., & Schmidt, B. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60242-6 · Cited by 663
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31821daaf6 · Cited by 614
Early recognition and prevention of chronic kidney disease
James, M. T., Hemmelgarn, B. R., & Tonelli, M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62004-3 · Cited by 606
Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556
Self-citationBakris, G. L., Sarafidis, P. A., Weir, M. R., Dahlöf, B., Pitt, B., Jamerson, K., Velazquez, E. J., Staikos-Byrne, L., Kelly, R. Y., Shi, V., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62100-0 · Cited by 523
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Ann Forciea, M., Frishman, W. H., Jaigobin, C., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.008 · Cited by 514
Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498
Xie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L., Lv, J., Zhang, H., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.011 · Cited by 479
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
“0 mg/dL.(395) Although ACEis are effective and widely used, some patients would have the side effects such as cough.”
BackgroundThe renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 433
Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citationAntihypertensive Therapy in the Presence of Proteinuria
Sarafidis, P. A., Khosla, N., & Bakris, G. L. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.10.014 · Cited by 364
“…compared with metoprolol Patients with baseline proteinuria Ͼ1 g/d in the low-goal group had slower GFR decline compared with those in usual-goal group Hou et al, 2006 47 Benazepril v placebo 224 26 1.6 3.4 y Benazepril associated with 43% reduction in risk of doubling of serum creatinine level,…”
ResultInfluentialImmune and Inflammatory Role in Renal Disease
Imig, J. D., & Ryan, M. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120028 · Cited by 356
“This is largely based on evidence showing that RAAS blockade reduces urinary protein and overall renal risk to a greater degree than other blood pressure lowering therapies in diabetic and non-diabetic nephropathies (99,128,274).”
Kovesdy, C. P., Matsushita, K., Sang, Y., Brunskill, N. J., Carrero, J. J., Chodick, G., Hasegawa, T., Heerspink, H. L., Hirayama, A., Landman, G. W. D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy100 · Cited by 346
Molecular pathways that drive diabetic kidney disease
Mohandes, S., Doke, T., Hu, H., Mukhi, D., Dhillon, P., & Susztak, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165654 · Cited by 341
“More than 20 years ago, blockers of the reninangiotensin-aldosterone system (RAAS) became a mainstay therapy, as they were shown to lower composite renal outcomes (death, dialysis, doubling of serum creatinine) by 20% (150).”
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.026 · Cited by 338
Self-citationCooperative N-Heterocyclic Carbene/Palladium-Catalyzed Enantioselective Umpolung Annulations
Guo, C., Fleige, M., Janssen-Müller, D., Daniliuc, C. G., & Glorius, F. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b04364 · Cited by 344
Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease
Bhandari, S., Mehta, S., Khwaja, A., Cleland, J. G. F., Ives, N., Brettell, E., Chadburn, M., & Cockwell, P. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210639 · Cited by 328
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
“These drugs work by inhibiting the activity of the angiotensin-converting enzyme (ACE), resulting in a lower generation of angiotensin II, a hormone that narrows the vessels and raises pressure.(332,333) Recently, researchers have shown that both benazepril and enalapril have the capacity to positively influence gut m…”
BackgroundSelf-citationMechanisms and Treatment of CKD
Ruggenenti, P., Cravedi, P., & Remuzzi, G. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012040390 · Cited by 286
Zannad, F., Ferreira, J. P., Pocock, S. J., Zeller, C., Anker, S. D., Butler, J., Filippatos, G., Hauske, S. J., Brueckmann, M., Pfarr, E., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051685 · Cited by 280
The next generation of therapeutics for chronic kidney disease
Breyer, M. D., & Susztak, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.67 · Cited by 272
Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Weir, M. R., & Rolfe, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07821109 · Cited by 265
“(25) in patients with nondiabetic CKD (proteinuria 300 mg/d) showed that in those with baseline serum creatinine 3.”
BackgroundHou, F. F., Xie, D., Zhang, X., Chen, P. Y., Zhang, W. R., Liang, M., Guo, Z. J., & Jiang, J. P. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121372 · Cited by 251
Self-citationStrauss, M. H., & Hall, A. S. (2006) · Circulation · doi:10.1161/circulationaha.105.594986 · Cited by 249
Caldeira, D., Alarcao, J., Vaz-Carneiro, A., & Costa, J. (2012) · BMJ · doi:10.1136/bmj.e4260 · Cited by 246
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242
Multiple Genes of the Renin-Angiotensin System Are Novel Targets of Wnt/β-Catenin Signaling
Zhou, L., Li, Y., Hao, S., Zhou, D., Tan, R. J., Nie, J., Hou, F. F., Kahn, M., & Liu, Y. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010085 · Cited by 237
Self-citationLv, J., Zhang, H., Chen, Y., Li, G., Jiang, L., Singh, A. K., & Wang, H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.029 · Cited by 238
Ahmed, A. K., Kamath, N. S., El Kossi, M., & El Nahas, A. M. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp511 · Cited by 226
Hsu, T.-W., Liu, J.-S., Hung, S.-C., Kuo, K.-L., Chang, Y.-K., Chen, Y.-C., Hsu, C.-C., & Tarng, D.-C. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12700 · Cited by 216
Effects of dapagliflozin in stage 4 chronic kidney disease
Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Gorriz, J. L., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021020167 · Cited by 201
Self-citationChiang, C.-E., Wang, T.-D., Ueng, K.-C., Lin, T.-H., Yeh, H.-I., Chen, C.-Y., Wu, Y.-J., Tsai, W.-C., Chao, T.-H., Chen, C.-H., et al. (2015) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2014.11.005 · Cited by 199
Management of hyperkalaemia in chronic kidney disease
Kovesdy, C. P. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.168 · Cited by 201
Qiao, Y., Shin, J.-I., Chen, T. K., Inker, L. A., Coresh, J., Alexander, G. C., Jackson, J. W., Chang, A. R., & Grams, M. E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0193 · Cited by 199
Wang, B.-L., Pan, D.-Q., Zhou, K.-L., Lou, Y.-Y., & Shi, J.-H. (2019) · Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2018.12.040 · Cited by 196
Mizobuchi, M., Morrissey, J., Finch, J. L., Martin, D. R., Liapis, H., Akizawa, T., & Slatopolsky, E. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006091028 · Cited by 196
Jose, P., Skali, H., Anavekar, N., Tomson, C., Krumholz, H. M., Rouleau, J. L., Moye, L., Pfeffer, M. A., & Solomon, S. D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010063 · Cited by 196
“Recent data have demonstrated the benefits of ACE inhibition in patients with advanced renal insufficiency, even when a patient’s serum creatinine level continues to increase (29,30).”
BackgroundWheeler, D. C., Stefansson, B. V., Batiushin, M., Bilchenko, O., Cherney, D. Z. I., Chertow, G. M., Douthat, W., Dwyer, J. P., Escudero, E., Pecoits-Filho, R., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa234 · Cited by 194
Self-citationFu, E. L., Evans, M., Clase, C. M., Tomlinson, L. A., van Diepen, M., Dekker, F. W., & Carrero, J. J. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050682 · Cited by 192
Bonner, R., Albajrami, O., Hudspeth, J., & Upadhyay, A. (2020) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2020.08.004 · Cited by 177
Solomon, S. D., Rice, M. M., A. Jablonski, K., Jose, P., Domanski, M., Sabatine, M., Gersh, B. J., Rouleau, J., Pfeffer, M. A., & Braunwald, E. (2006) · Circulation · doi:10.1161/circulationaha.105.592733 · Cited by 190
Raebel, M. A. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 188
Axially Chiral Dibenzazepinones by a Palladium(0)‐Catalyzed Atropo‐enantioselective C−H Arylation
Newton, C. G., Braconi, E., Kuziola, J., Wodrich, M. D., & Cramer, N. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201806527 · Cited by 170
Appel, L. J. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.832 · Cited by 167
Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164
Ciani, O., Buyse, M., Garside, R., Pavey, T., Stein, K., Sterne, J. A. C., & Taylor, R. S. (2013) · BMJ · doi:10.1136/bmj.f457 · Cited by 165
Stage IV Chronic Kidney Disease
Abboud, H., & Henrich, W. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0906797 · Cited by 163
Molnar, M. Z., Kalantar-Zadeh, K., Lott, E. H., Lu, J. L., Malakauskas, S. M., Ma, J. Z., Quarles, D. L., & Kovesdy, C. P. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.050 · Cited by 163
“Clinical trials of ACEI and/or ARB that included CKD patients with more advanced stages examined primarily renal and composite renal outcomes (which sometimes included mortality), but not mortality alone.(6-9,12,25) An earlier meta-analysis of smaller RCTs examining primarily the effect of ACEI on progression of non-d…”
Cardiovascular–renal axis disorders in the domestic dog and cat: a veterinary consensus statement
Pouchelon, J. ‐., Atkins, C. E., Bussadori, C., Oyama, M. A., Vaden, S. L., Bonagura, J. D., Chetboul, V., Cowgill, L. D., Elliot, J., Francey, T., et al. (2015) · Journal of Small Animal Practice · doi:10.1111/jsap.12387 · Cited by 227
“…disease, diabetic nephropathy, hypertensive nephropathy, nephrosclerosis, interstitial nephritis and polycystic kidney disease (Maschio et al. 1996, Hou et al. 2006)) do not correlate exactly to those seen in veterinary patients (dogs: glomerular disease, pyelonephritis, acute tubular necrosis,…”
ResultInker, L. A., Heerspink, H. J. L., Mondal, H., Schmid, C. H., Tighiouart, H., Noubary, F., Coresh, J., Greene, T., & Levey, A. S. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.017 · Cited by 164
“C20(23) 584 CKD 52 6 12 228 (39) 53 (9) 40.”
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G. L., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C. S., et al. (2011) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2011.06.001 · Cited by 172
Heerspink, H. J. L., Tighiouart, H., Sang, Y., Ballew, S. H., Mondal, H., Matsushita, K., Coresh, J., Levey, A. S., & Inker, L. A. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.018 · Cited by 149
Palladium‐Catalyzed Oxidative Cycloaddition through CH/NH Activation: Access to Benzazepines
Wang, L., Huang, J., Peng, S., Liu, H., Jiang, X., & Wang, J. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201208076 · Cited by 138
Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System
Chang, A. R., Sang, Y., Leddy, J., Yahya, T., Kirchner, H. L., Inker, L. A., Matsushita, K., Ballew, S. H., Coresh, J., & Grams, M. E. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07363 · Cited by 139
Inker, L. A., Levey, A. S., Pandya, K., Stoycheff, N., Okparavero, A., & Greene, T. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.02.020 · Cited by 133
Bhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G., Khwaja, A., & El Nahas, M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv346 · Cited by 127
Medication Safety Principles and Practice in CKD
Whittaker, C. F., Miklich, M. A., Patel, R. S., & Fink, J. C. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00580118 · Cited by 141
Herrington, W. G., Judge, P. K., Grams, M. E., & Wanner, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01942-7 · Cited by 150
Chen, M., Chen, Y., Sun, N., Zhao, J., Liu, Y., & Li, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201410056 · Cited by 121
Global case studies for chronic kidney disease/end-stage kidney disease care
Yang, C., Harris, D. C. H., Luyckx, V. A., Nangaku, M., Hou, F. F., García-García, G., Abu-Aisha, H., Niang, A., Solá, L., Bunnag, S., et al. (2020) · Kidney International Supplements · doi:10.1016/j.kisu.2019.11.010 · Cited by 139
“5 to 7 years.(30) Uptitration of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker dosages against albuminuria confers further benefit on kidney outcomes in patients with nondiabetic CKD and kidney insufficiency.”
BackgroundSelf-citationAngiotensin-Converting Enzyme Inhibitors
Izzo, J. L., & Weir, M. R. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00508.x · Cited by 138
“fits of ACE inhibition persist during the progression of nondiabetic kidney disease irrespective of the initial level of serum creatinine, and the incidence of serious adverse events including hyperkalemia remains low.(67)”
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Weinberg, J. M. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.284 · Cited by 115
Eckardt, K., Bansal, N., Coresh, J., Evans, M., Grams, M. E., Herzog, C. A., James, M. T., Heerspink, H. J. L., Pollock, C. A., Stevens, P. E., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.02.006 · Cited by 130
Yu, L., Xu, Q., Tang, X.-Y., & Shi, M. J. (2015) · ACS Catalysis · doi:10.1021/acscatal.5b02400 · Cited by 114
Synthesis of Ring-Fused 1-Benzazepines via [1,5]-Hydride Shift/7-Endo Cyclization Sequences
Suh, C. W., Kwon, S. J., & Kim, D. Y. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b00184 · Cited by 114
O’Hare, A. M., Kaufman, J. S., Covinsky, K. E., Landefeld, C. S., McFarland, L. V., & Larson, E. B. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00010 · Cited by 118
“…Sponsor Women, %† Mean Age, y† Entry Criteria Age (Range), y Proteinuria (Mean or Median Value) Hypertension Diabetes Mellitus Renal Function (Mean) Hou et al, 2006 (51) Benazepril vs. placebo 224 3.4 y Industry, government 51 45 18–70 PER 300 mg/d (mean PER, 1.7 g/d) NS (91.5% hypertension)…”
InfluentialPopulation-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis
Cusick, M. M., Tisdale, R. L., Chertow, G. M., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3228 · Cited by 131
Maione, A., Navaneethan, S. D., Graziano, G., Mitchell, R. L., Johnson, D. W., Mann, J. F. E., Gao, P., Craig, J. C., Tognoni, G., Perkovic, V., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq792 · Cited by 123
“Hou [46] Macro 91.”
BackgroundThe Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge
Borg, R., Carlson, N., Søndergaard, J., & Persson, F. (2023) · International Journal of Nephrology · doi:10.1155/2023/9609266 · Cited by 147
Bangalore, S., Kumar, S., & Messerli, F. H. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.06.014 · Cited by 120
Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report
Weir, M. R., Lakkis, J. I., Jaar, B. G., Rocco, M. V., Choi, M. J., Kramer, H., & Ku, E. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.010 · Cited by 110
Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade
Griffin, K. A., & BIDANI, A. K. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02231205 · Cited by 103
“This relative inferiority of a CCB-based regimen is likely to be particularly true in patients with advanced proteinuric CKD, such as the participants in the recently reported trial from China (80).”
Weir, M. R. (2021) · American Journal of Nephrology · doi:10.1159/000516901 · Cited by 116
Current Therapy for IgA Nephropathy
Floege, J., & Eitner, F. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011030221 · Cited by 97
Song, L., Zhang, W., Tang, S., Luo, S., Xiong, P., Liu, J., Hu, H., Chen, Y., Jia, B., Yan, Q., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116039 · Cited by 96
Self-citationTreatment of IgA nephropathy and Henoch–Schönlein nephritis
Floege, J., & Feehally, J. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.59 · Cited by 94
Pathogenesis of Chronic Cardiorenal Syndrome: Is There a Role for Oxidative Stress?
Rubattu, S., Mennuni, S., Testa, M., Mennuni, M., Pierelli, G., Pagliaro, B., Gabriele, E., Coluccia, R., Autore, C., & Volpe, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141123011 · Cited by 88
“Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and aldosterone receptor antagonists, as well as β-blockers, have clearly emerged as cornerstones of chronic HF therapy [119–129].”
BackgroundDiabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy
Masoudi, F. A., & Inzucchi, S. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.013 · Cited by 97
Atherosclerosis in chronic kidney disease: the role of macrophages
Kon, V., Linton, M. F., & Fazio, S. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.157 · Cited by 88
Advances in the management of chronic kidney disease
Chen, T. K., Hoenig, M. P., Nitsch, D., & Grams, M. E. (2023) · BMJ · doi:10.1136/bmj-2022-074216 · Cited by 122
Therapeutic Insights in Chronic Kidney Disease Progression
Shabaka, A., Cases‐Corona, C., & Juarez, G. M. F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.645187 · Cited by 96
“Serious hyperkalemia was similar with benazepril and placebo (15).”
BackgroundBowling, C. B., Sanders, P. W., Allman, R. M., Rogers, W. J., Patel, K., Aban, I. B., Rich, M. W., Pitt, B., White, M., Bakris, G. C., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.12.056 · Cited by 85
“Further, ACEIs have also been shown to reduce renal failure and prevent death in patients with CKD [16].”
BackgroundVerbeke, F., Lindley, E., Bortel, L. M. V., Vanholder, R. C., London, G. M., Cochat, P., Więcek, A., Fouque, D. P., & Biesen, W. V. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft321 · Cited by 86
“This is based on a post hoc analysis of the RENAAL study [8] (Table 2) and an RCT in Chinese non-diabetic CKD 4 patients [9], which showed a favourable effect on renal outcome and mortality when treating these patients with an ARB and ACE-I, respectively.”
MethodXie, Y., & Chen, X. (2007) · American Journal of Nephrology · doi:10.1159/000108755 · Cited by 89
“Compared with placebo, benazepril (BZ) was associated with a 43p reduction in the risk of the primary end point (a doubling of the serum creatinine level, ESRD or death), a 52p reduction in the level of proteinuria and a 23p reduction in the rate of decline in renal function in Chinese patients with serum creatinine l…”
ResultInfluentialBerger, A. K., Duval, S., Manske, C. L., Vazquez, G., Barber, C. A., Miller, L. W., & Luepker, R. V. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.03.017 · Cited by 88
“and ARB are underused in patients with CHF and coexistent CKD; (2) the inhospital use of ACE-I and ARB in patients with CHF and severe renal insufficiency is associated with a significant reduction in 30-day mortality;and ( 3 ) the discharge prescription of ACE-I andARB in patients with CHF and severe renal insufficie…”
BackgroundKidney aging—inevitable or preventable?
Choudhury, D., & Levi, M. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.104 · Cited by 89
“Use of ACE inhibitors and ARBs in patients with diabetic and nondiabetic proteinuria is beneficial in decreasing the rate of GFR loss”
MethodHow Tubular Epithelial Cell Injury Contributes to Renal Fibrosis
Liu, B., Tang, T., & Lv, L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_11 · Cited by 89
Vart, P., Vaduganathan, M., Jongs, N., Remuzzi, G., Wheeler, D. C., Hou, F. F., Causland, F. R. M., Chertow, G. M., & Heerspink, H. J. L. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08900722 · Cited by 82
“1Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 2Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 3Cardiovascular Division, Brigham andWomen’s Hospital, H…”
MethodSelf-citationHusain, K. M., Ferder, L., Mizobuchi, M., Finch, J. L., & Slatopolsky, E. (2008) · American Journal of Nephrology · doi:10.1159/000178251 · Cited by 91
“Since the RAAS has an essential role in both renal as well as cardiovascular pathophysiology, agents that inhibit this system such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), have been shown to have beneficial effects in patients with both chronic renal and cardiova…”
BackgroundSmall molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective
Zheng, W., Tian, E., Liu, Z., Zhou, C., Yang, P., Tian, K., Liao, W., Li, J., & Ren, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.968104 · Cited by 96
Self-citation
Metadata
- Authors
- Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., & Geng, R. W.
- Affiliations
- Nanfang Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-12
- Volume
- 354
- Issue
- 2
- Pages
- 131-140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2063210769
- Cited by
- 710
- References
- 22
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 31 · 2023: 42 · 2022: 42 · 2021: 43 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 23 · 2016: 29 · 2015: 24 · 2014: 39 · 2013: 30 · 2012: 39
- FWCI
- 31.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- benazepril, ACE inhibitors, end-stage renal disease, renal protection, proteinuria, renal function decline, serum creatinine doubling, non-diabetic patients, adverse events
- MeSH terms
- Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzazepines, Blood Pressure, China, Creatinine, Double-Blind Method, Female, Humans, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.